The most successful results have been obtained in ovarian cancer, where DPX-Survivac, a vaccine based on the use of survivin peptides in conjunction with a DepoVaxTM adjuvant, administrated in a treatment together with cyclophosphamide, yielded favorable results in a phase I clinical trial. The gene discussed is BIRC5; the disease is ovarian carcinoma.